Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.62 |
| ▸ | TSHR | P16473 | 5/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | G6PD | P11413 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | CRHBP | P24387 | 2/20 | 0.44 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | PDE2A | O00408 | 1/20 | 0.44 |
| ▸ | PDE5A | O76074 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16971089 | 0.85 | ALDH1A1 (0.59) | ALDH1A1TSHRTDP1CYP3A4HPGD | |
| SCHEMBL16971064 | 0.85 | ALDH1A1 (0.58) | ALDH1A1TSHRTDP1CYP3A4HPGD | |
| SCHEMBL12929973 | 0.85 | ALDH1A1 (0.62) | ALDH1A1TSHRTDP1CYP3A4HPGD | |
| SCHEMBL11526155 | 0.84 | ALDH1A1 (0.51) | ALDH1A1TSHRTDP1CYP3A4HPGD | |
| SCHEMBL18993988 | 0.83 | ALDH1A1 (0.60) | ALDH1A1TSHRTDP1CYP3A4HPGD | |
| SCHEMBL22604452 | 0.82 | ALDH1A1 (0.55) | ALDH1A1TSHRTDP1CYP3A4MAPT | |
| SCHEMBL16971211 | 0.81 | ALDH1A1 (0.53) | ALDH1A1TSHRTDP1CYP3A4HPGD | |
| SCHEMBL9735630 | 0.81 | PDK1 (0.55) | ALDH1A1TSHRTDP1CYP3A4HPGD | |
| SCHEMBL19592246 | 0.80 | ALDH1A1 (0.56) | ALDH1A1TSHRTDP1CYP3A4MAPT | |
| SCHEMBL21316561 | 0.80 | ALDH1A1 (0.51) | ALDH1A1TSHRTDP1CYP3A4HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11744832-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE CORPORATION (US) | 2023-09-05 | — | — | US | disclosed |
| US-11744832-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE CORPORATION (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230276701-A1 | ORGANIC COMPOUND AND ORGANIC LIGHT EMISSION DEVICE | OSAKA UNIVERSITY (JP) | 2023-08-31 | — | — | US | disclosed |
| CN-116179614-A | Preparation method and application of O-cymene-5-ol for cosmetics | 王叔和生物医药(武汉)有限公司 | 2023-05-30 | — | — | CN | disclosed |
| US-20220395506-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION | 2022-12-15 | — | — | US | disclosed |
| US-10639310-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE CORPORATION (US) | 2020-05-05 | — | — | US | disclosed |
| US-20190125750-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION | 2019-05-02 | — | — | US | disclosed |
| US-9974790-B2 | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors | INCYTE CORPORATION (US) | 2018-05-22 | — | — | US | disclosed |
| US-9975852-B2 | Quinoline sulfonyl derivatives and uses thereof | HEALTH SCIENCES NORTH RESEARCH INSTITUTE (CA) | 2018-05-22 | — | — | US | disclosed |
| US-9974790-B2 | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors | INCYTE CORPORATION (US) | 2018-05-22 | — | — | US | disclosed |
| US-20110224157-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION, A DELAWARE CORPORATION | 2011-09-15 | — | — | US | disclosed |
| WO-2011008618-A1 | METAL-CATALYZED CARBON-FLUORINE BOND FORMATION | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2011-01-20 | — | — | WO | disclosed |
| US-20110015401-A1 | Metal-Catalyzed Carbon-Fluorine Bond Formation | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2011-01-20 | — | — | US | disclosed |
| US-20100022522-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | Incyte Corporationn, a Delaware corporation | 2010-01-28 | — | — | US | disclosed |
| US-20100022522-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | Incyte Corporationn, a Delaware corporation | 2010-01-28 | — | — | US | disclosed |
| US-7598257-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors | INCYTE CORPORATION (US) | 2009-10-06 | — | — | US | disclosed |
| US-20090181959-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-07-16 | — | — | US | disclosed |
| US-20090181959-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-07-16 | — | — | US | disclosed |
| WO-2007070514-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-B]PYRIDINES AND PYRROLO[2,3-B]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2007-06-21 | — | — | WO | disclosed |
| US-20070135461-A1 | 3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile; immune-related diseases, skin disorders, myeloid proliferative disorders, cancer | INCYTE CORPORATION | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10639310-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | JAK3, JAK1, JAK2 | ALDH1A1 3413/4885TSHR 3192/4885TDP1 1172/4885 |
| US-20220395506-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | ALDH1A1 3413/4885TSHR 3192/4885TDP1 1172/4885 |
| US-20190125750-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | ALDH1A1 3413/4885TSHR 3192/4885TDP1 1172/4885 |
| US-20110224157-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | ALDH1A1 3413/4885TSHR 3192/4885TDP1 1172/4885 |
| US-20230276701-A1 | ORGANIC COMPOUND AND ORGANIC LIGHT EMISSION DEVICE | ESR1, ECE1, ESYT1 | ALDH1A1 722/4885TSHR 3456/4885TDP1 1308/4885 |
| US-20110015401-A1 | Metal-Catalyzed Carbon-Fluorine Bond Formation | FLI1, VGF, GMFG | ALDH1A1 1100/4885TSHR 3434/4885TDP1 4454/4885 |
| US-20070135461-A1 | 3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile; immune-related diseases, skin disorders, myeloid proliferative disorders, cancer | JAK1, JAK3, MAP3K4 | ALDH1A1 2035/4885TSHR 3399/4885TDP1 1298/4885 |
| US-11744832-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | JAK3, JAK1, JAK2 | ALDH1A1 3413/4885TSHR 3192/4885TDP1 1172/4885 |
| US-20100022522-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | ALDH1A1 3413/4885TSHR 3192/4885TDP1 1172/4885 |
| US-20090181959-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | ALDH1A1 3413/4885TSHR 3192/4885TDP1 1172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.